INDRAPRASTHA MEDICAL 2018-19 Annual Report Analysis

Fri, 18 Oct

INDRAPRASTHA MEDICAL has announced its results for the year ended March 2019. Let us have a look at the detailed performance review of the company during FY18-19.

INDRAPRASTHA MEDICAL Income Statement Analysis

• Operating income during the year rose 4.7% on a year-on-year (YoY) basis.
• The company's operating profit increased by 11.0% YoY during the fiscal. Operating profit margins witnessed a growth and stood at 10.2% in FY19 as against 9.7% in FY18.
• Depreciation charges decreased by 3.0% and finance costs decreased by 22.8% YoY, respectively.
• Other income declined by 41.0% YoY.
• Net profit for the year grew by 34.6% YoY.
• Net profit margins during the year grew from 2.8% in FY18 to 3.6% in FY19.

INDRAPRASTHA MEDICAL Income Statement 2018-19

DISCOVER: How to Potentially Multiply Your Returns by Upto 5x...

INDRAPRASTHA MEDICAL Balance Sheet Analysis

• The company's current liabilities during FY19 down at Rs 1 billion as compared to Rs 1 billion in FY18, thereby witnessing an decrease of -10.4%.
• Long-term debt down at Rs 150 million as compared to Rs 210 million during FY18, a fall of 28.6%.
• Current assets rose 2% and stood at Rs 1 billion, while fixed assets fell 4% and stood at Rs 3 billion in FY19.
• Overall, the total assets and liabilities for FY19 stood at Rs 4 billion as against Rs 4 billion during FY18, thereby witnessing a fall of 2%.

INDRAPRASTHA MEDICAL Balance Sheet as on March 2019

INDRAPRASTHA MEDICAL Cash Flow Statement Analysis

• INDRAPRASTHA MEDICAL's cash flow from operating activities (CFO) during FY19 stood at Rs 752 million, an improvement of 57.6% on a YoY basis.
• Cash flow from investing activities (CFI) during FY19 stood at Rs -167 million on a YoY basis.
• Cash flow from financial activities (CFF) during FY19 stood at Rs -442 million on a YoY basis.
• Overall, net cash flows for the company during FY19 stood at Rs 143 million from the Rs 6 million net cash flows seen during FY18.

INDRAPRASTHA MEDICAL Cash Flow Statement 2018-19

Current Valuations for INDRAPRASTHA MEDICAL

• The trailing twelve-month earnings per share (EPS) of the company stands at Rs 3.1, an improvement from the EPS of Rs 2.3 recorded last year.
• The price to earnings (P/E) ratio, at the current price of Rs 36.1, stands at 10.9 times its trailing twelve months earnings.
• The price to book value (P/BV) ratio at current price levels stands at 1.7 times, while the price to sales ratio stands at 0.5 times.
• The company's price to cash flow (P/CF) ratio stood at 5.7 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

Ratio Analysis for INDRAPRASTHA MEDICAL

• Solvency Ratios

Current Ratio: The company's current ratio improved and stood at 1.1x during FY19, from 1.0x during FY18. The current ratio measures the company's ability to pay short-term and long-term obligations.

Interest Coverage Ratio: The company's interest coverage ratio improved and stood at 7.5x during FY19, from 4.8x during FY18. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

• Profitability Ratios

Return on Equity (ROE): The ROE for the company improved and stood at 11.6% during FY19, from 9.1% during FY19. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 19.9% during FY19, from 16.9% during FY18. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

Return on Assets (ROA): The ROA of the company improved and stood at 8.4% during FY19, from 6.9% during FY18. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

To see how INDRAPRASTHA MEDICAL has performed over the last 5 years, please visit here.

INDRAPRASTHA MEDICAL Share Price Performance

Over the last one year, INDRAPRASTHA MEDICAL share price has moved down from Rs 40.4 to Rs 36.1, registering a loss of Rs 4.3 or around 10.6%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,628.2 (up 1.0%). Over the last one year it has moved down from 14,640.1 to 12,628.2, a loss of 2,012 points (down 13.7%).

Overall, the S&P BSE SENSEX is up 12.8% over the year.

(To know more, check out historical annual results for INDRAPRASTHA MEDICAL and quarterly results for INDRAPRASTHA MEDICAL)